Table 1.
Characteristics of patients.
| BCa | Previous BCa | No CaBD | p-Value | |
|---|---|---|---|---|
|
Age (years),
median (IQR) |
71 (57–73) | 69.5 (64–75) | 66.5 (57–73) | 0.0007 * |
| Gender (M/F), n | 177/31 | 71/17 | 67/33 | 0.001 ** |
| BMI | 26.6 (24.1–29.4) | 27 (24.7–29.2) | 26.7 (24.1–29.4) | 0.65 * |
| Triglycerides/HDL Ratio | 2.5 (1.8–4) | 2.1 (1.6–3.5) | 2.1 (1.3–2.8) | 0.023 * |
| PChE (U/L) | 8660 (7605–10,088) | 9440 (8440–10,979) | 9497 (8538–10,993) | 0.0005 * |
| Glucose (mg/dL) | 97 (87–115) | 97 (85–109) | 91.5 (81–108) | 0.15 * |
| Total Cholesterol (mg/dL) |
172.5 (148–203) | 175.5 (152–216) | 185 (160–209) | 0.12 * |
| LDL Cholesterol (mg/dL) |
107 (81–134) | 115.5 (90–150) | 116 (93–138) | 0.11 * |
|
HDL Cholesterol
(mg/dL) |
42 (36–49) | 47 (37.5–56) | 46 (40–55) | 0.0065 * |
|
Triglycerides
(mg/dL) |
112 (84–144) | 106.5 (77–140) | 97.5 (75–127.5) | 0.03 * |
|
Uric Acid
(mg/dL) |
5.8 (4.7–6.8) | 5.5 (4.6–6.8) | 5.3 (4.4–5–9) | 0.046 * |
| Ferritin (ng/mL) |
89 (43–176) | 71.5 (43.5–114) | 83 (35.5–136.5) | 0.28 * |
|
Creatinine
(mg/dL) |
1 (0.8–1.2) | 0.9 (0.8–1–1) | 0.8 (0.7–1) | 0.0002 * |
| T2DM, n | 50 | 15 | 15 | 0.127 ** |
| Hypertension, n | 131 | 54 | 51 | 0.124 ** |
| GGT (U/L | 20 (15–32) | 19 (16–29) | 22 (15–30) | 0.8 * |
| ALT (U/L) | 18 (13–22) | 17 (12–23) | 18 (13–22) | 0.55 * |
| AST (U/L) | 19 (15–22) | 19 (17–23) | 18 (15–22) | 0.34 * |
| ALP (U/L) | 81 (67–99) | 74 (63–87) | 80 (66–101) | 0.16 * |
| LDH (U/L) | 186 (165–212) | 193 (172–222) | 180 (158–208) | 0.01 * |
| Platelets (103/uL) | 205 (168.5–246.5) | 213 (178.5–230) | 216 (178–266) | 0.16 * |
* Kruskal–Wallis H test. ** Pearson’s chi-squared. n, number; BCa, bladder cancer; no CaBD, no cancer but bladder disease; GGT, gamma-glutamyl transferase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; PChE, pseudocholinesterase; ALP, alkaline phosphatase; T2DM, type 2 diabetes mellitus.